- Previous Close
9.25 - Open
9.01 - Bid --
- Ask --
- Day's Range
8.70 - 9.40 - 52 Week Range
8.70 - 18.75 - Volume
205,235 - Avg. Volume
41,216 - Market Cap (intraday)
118.818M - Beta (5Y Monthly) 3.38
- PE Ratio (TTM)
-- - EPS (TTM)
-0.81 - Earnings Date Apr 14, 2025 - Apr 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
38.00
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
greenwichlifesciences.comRecent News: GLSI
View MorePerformance Overview: GLSI
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLSI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLSI
View MoreValuation Measures
Market Cap
122.18M
Enterprise Value
116.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
24.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-89.85%
Return on Equity (ttm)
-151.72%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.5M
Diluted EPS (ttm)
-0.81
Balance Sheet and Cash Flow
Total Cash (mrq)
5.82M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.8M